Monoclonal antibody therapies against SARS-CoV-2
Monoclonal antibodies (mAbs) targeting the spike protein of SARS-CoV-2 have been widely
used in the ongoing COVID-19 pandemic. In this paper, we review the properties of mAbs …
used in the ongoing COVID-19 pandemic. In this paper, we review the properties of mAbs …
[HTML][HTML] Convergent evolution in SARS-CoV-2 spike creates a variant soup from which new COVID-19 waves emerge
The first 2 years of the COVID-19 pandemic were mainly characterized by recurrent
mutations of SARS-CoV-2 Spike protein at residues K417, L452, E484, N501 and P681 …
mutations of SARS-CoV-2 Spike protein at residues K417, L452, E484, N501 and P681 …
[HTML][HTML] Recombination in Coronaviruses, with a Focus on SARS-CoV-2
Recombination is a common evolutionary tool for RNA viruses, and coronaviruses are no
exception. We review here the evidence for recombination in SARS-CoV-2 and reconcile …
exception. We review here the evidence for recombination in SARS-CoV-2 and reconcile …
[HTML][HTML] Mucosal vaccines, sterilizing immunity, and the future of SARS-CoV-2 virulence
Sterilizing immunity after vaccination is desirable to prevent the spread of infection from
vaccinees, which can be especially dangerous in hospital settings while managing frail …
vaccinees, which can be especially dangerous in hospital settings while managing frail …
[HTML][HTML] Passive immunotherapy against SARS-CoV-2: from plasma-based therapy to single potent antibodies in the race to stay ahead of the variants
The COVID-19 pandemic is now approaching 2 years old, with more than 440 million people
infected and nearly six million dead worldwide, making it the most significant pandemic …
infected and nearly six million dead worldwide, making it the most significant pandemic …
Spike-protein proteolytic antibodies in COVID-19 convalescent plasma contribute to SARS-CoV-2 neutralization
Understanding the mechanisms of antibody-mediated neutralization of SARS-CoV-2 is
critical in combating the COVID-19 pandemic. Based on previous reports of antibody …
critical in combating the COVID-19 pandemic. Based on previous reports of antibody …
[HTML][HTML] Clinical management of patients with B-cell depletion agents to treat or prevent prolonged and severe SARS-COV-2 infection: defining a treatment pathway
A D'Abramo, S Vita, G Maffongelli… - Frontiers in …, 2022 - frontiersin.org
Introduction Immunocompromised patients with B-cell depletion agents are at risk for
persistence and/or severe SARS-COV-2 infection. We describe a case series of 21 COVID …
persistence and/or severe SARS-COV-2 infection. We describe a case series of 21 COVID …
[HTML][HTML] Potent universal beta-coronavirus therapeutic activity mediated by direct respiratory administration of a Spike S2 domain-specific human neutralizing …
Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2) marks the third novel β-
coronavirus to cause significant human mortality in the last two decades. Although vaccines …
coronavirus to cause significant human mortality in the last two decades. Although vaccines …
[HTML][HTML] Prescription of anti-spike monoclonal antibodies in COVID-19 patients with resistant SARS-CoV-2 variants in Italy
Anti-Spike monoclonal antibodies have been considered a promising approach to COVID-
19 therapy. Unfortunately, the advent of resistant lineages jeopardized their effectiveness …
19 therapy. Unfortunately, the advent of resistant lineages jeopardized their effectiveness …
SARS‐CoV‐2 intrahost evolution in immunocompromised patients in comparison with immunocompetent populations after treatment
AS Ahmadi, S Zadheidar, K Sadeghi… - Journal of Medical …, 2023 - Wiley Online Library
Many evidence suggests that long‐lasting infection can develop with severe acute
respiratory syndrome coronavirus 2 (SARS‐CoV‐2). This occurrence has been widely …
respiratory syndrome coronavirus 2 (SARS‐CoV‐2). This occurrence has been widely …